NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive

NovoCure Ltd

2024-Q2 EPS reported -$0.67 revenue$288,859,000

Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.
Net loss $33.4M ($0.31 per share); adjusted EBITDA $1.1M; cash and investments $951.2M.
Phase 3 METIS trial in brain metastases from NSCLC met primary endpoint; presented at ASCO 2024.
Active patients 3,963 as of June 30, 2024; prescriptions 1,634, up 5% YoY.
Gross margin 77%; research & development expenses $55.0M; sales & marketing $56.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.